MedTrace Logo

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

NCT02448771 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-10-24

Study results available
· View outcomes & findings →

Summary

This research study is studying a drug called Palbociclib in combination with Bazedoxifene (a type of endocrine therapy, which prevents breast cancer cell growth by blocking estrogen stimulation) as a possible treatment for this diagnosis.

The names of the study interventions involved in this study are:

* Palbociclib
* Bazedoxifene

Conditions

  • Breast Cancer Stage IV
  • Unresectable Locally Advanced Invasive Breast Cancer
  • Metastatic Invasive Breast Cancer

Interventions

DRUG

Palbociclib

DRUG

Bazedoxifene

Sponsors & Collaborators

Principal Investigators

  • Rinath Jelsohn, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-09
Primary Completion
2019-08-12
Completion
2021-03-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02448771 on ClinicalTrials.gov